Maejima M, Fujii T, Yamashita T, Hara N, Hamai Y, Miki A, Kozuma S, Okai T, Shibata Y, Taketani Y
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Japan.
Am J Reprod Immunol. 1998 Jan;39(1):12-5. doi: 10.1111/j.1600-0897.1998.tb00327.x.
The appropriate modality of immunotherapy with the husband's mononuclear cells in women with a history of recurrent abortion who aborted despite the immunotherapy performed before pregnancy was explored.
Nineteen patients who had suffered from recurrent abortion who had received the immunotherapy only before pregnancy and had aborted were treated with further immunotherapy performed either only before pregnancy or twice: before and during pregnancy.
In 9 out of the 19 women who received further immunotherapy before pregnancy, 2 had healthy babies and 7 aborted again. In the remaining 10 patients who received further immunotherapy twice, before and during pregnancy, 8 had healthy babies and 2 aborted again.
Our results indicate that immunotherapy performed before and during pregnancy produces a better outcome compared with that performed only before pregnancy, especially in patients who showed no benefit from the immunotherapy performed only before pregnancy.
探讨了对于有复发性流产病史且尽管在妊娠前已进行免疫治疗仍发生流产的女性，采用其丈夫的单核细胞进行免疫治疗的合适方式。
19例有复发性流产病史的患者，她们仅在妊娠前接受过免疫治疗且发生了流产，对其进行进一步免疫治疗，治疗方式为仅在妊娠前进行或分两次进行：妊娠前和妊娠期间。
在19例妊娠前接受进一步免疫治疗的女性中，9例中有2例产下健康婴儿，7例再次流产。其余10例在妊娠前和妊娠期间分两次接受进一步免疫治疗的患者中，8例产下健康婴儿，2例再次流产。
我们的结果表明，与仅在妊娠前进行免疫治疗相比，妊娠前和妊娠期间进行免疫治疗可产生更好的结果，尤其是对于那些仅在妊娠前进行免疫治疗无获益的患者。
